Format

Send to

Choose Destination
J Thorac Oncol. 2017 Sep;12(9):1357-1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17.

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

Author information

1
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: CBC1971@yuhs.ac.
2
Seoul National University Hospital, Seoul, Republic of Korea.
3
Oncological Reference Center-IRCC, Aviano, Italy.
4
Ottawa Hospital Cancer Centre, Ottawa, Canada.
5
University of Auckland, Auckland, New Zealand.
6
Company Hospital-University Major of Charity of Novara, Novara, Italy.
7
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
8
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
9
Hotel Dieu de France University Hospital, Beirut, Lebanon, France.
10
S.Orsola-Malpighi University Hospital, Bologna, Italy.
11
IRCCS House Relief of Suffering, San Giovanni Rotondo, San Giovanni Rotondo (FG), Italy.
12
Newcastle University, Newcastle, United Kingdom.
13
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
14
Novartis Pharma AG, Basel, Switzerland.
15
Medical University of Gdańsk, Gdańsk, Poland.

Abstract

INTRODUCTION:

Ceritinib, 750 mg fasted, is approved for treatment of patients with ALK receptor tyrosine kinase gene (ALK)-rearranged (ALK-positive) NSCLC previously treated with crizotinib. Part 1 of the ASCEND-8 study determined whether administering ceritinib, 450 mg or 600 mg, with a low-fat meal may enhance gastrointestinal (GI) tolerability versus 750 mg fasted in patients with ALK-positive NSCLC while maintaining similar exposure.

METHODS:

ASCEND-8 is a multicenter, randomized, open-label, phase 1 study. Part 1 investigated the steady-state pharmacokinetics (PK) and safety of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg fasted in patients with advanced ALK-positive NSCLC who were either treatment naive or pretreated with chemotherapy and/or crizotinib. Part 2 will assess efficacy and safety of ceritinib in treatment-naive patients.

RESULTS:

As of June 16, 2016, 137 patients were randomized (450 mg fed [n = 44], 600 mg fed [n = 47], and 750 mg fasted [n = 46]); 135 patients received ceritinib. Median follow-up duration was 4.14 months. At steady state, relative to 750 mg fasted, 450 mg with food demonstrated comparable PK as assessed by maximum (peak) concentration of drug in plasma and area under the plasma concentration-time curve from time zero to 24 hours, whereas 600 mg with food demonstrated approximately 25% higher PK. Relative to 750 mg fasted, 450 mg with food was associated with a lower proportion of patients with GI toxicities, mostly grade 1 (diarrhea [43.2%], nausea [29.5%], and vomiting [18.2%]); there were no grade 3 or 4 events, study drug discontinuations, or serious AEs due to GI toxicities.

CONCLUSION:

Ceritinib, 450 mg with food, had similar exposure and a more favorable GI safety profile than ceritinib, 750 mg in fasted patients with ALK-positive NSCLC.

KEYWORDS:

Anaplastic lymphoma kinase; Ceritinib; Food-effect study; NSCLC

Comment in

PMID:
28729021
DOI:
10.1016/j.jtho.2017.07.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center